vs
Side-by-side financial comparison of OSR Holdings, Inc. (OSRH) and PAVmed Inc. (PAVM). Click either name above to swap in a different company.
PAVmed Inc. is the larger business by last-quarter revenue ($996.0K vs $627.7K, roughly 1.6× OSR Holdings, Inc.). PAVmed Inc. runs the higher net margin — 6465.8% vs -508.9%, a 6974.7% gap on every dollar of revenue. On growth, PAVmed Inc. posted the faster year-over-year revenue change (25.9% vs -23.7%).
PAVmed Inc. is a commercial-stage medical technology company that designs, develops and commercializes innovative diagnostic and therapeutic medical products. Its portfolio covers point-of-care diagnostics, interventional oncology and gastroenterology solutions, primarily serving healthcare providers and patients across the United States.
OSRH vs PAVM — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $627.7K | $996.0K |
| Net Profit | $-3.2M | $64.4M |
| Gross Margin | 41.7% | -38.7% |
| Operating Margin | -605.9% | -1162.4% |
| Net Margin | -508.9% | 6465.8% |
| Revenue YoY | -23.7% | 25.9% |
| Net Profit YoY | -1283.3% | 464.4% |
| EPS (diluted) | $0.12 | $1.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $627.7K | — | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $761.3K | — | ||
| Q3 24 | $823.0K | $996.0K | ||
| Q2 24 | $881.8K | $979.0K | ||
| Q1 24 | $910.2K | $1.0M | ||
| Q4 23 | — | $1.0M | ||
| Q3 23 | — | $791.0K |
| Q3 25 | $-3.2M | — | ||
| Q2 25 | $-5.2M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q3 24 | $-231.0K | $64.4M | ||
| Q2 24 | $-97.3K | $-10.8M | ||
| Q1 24 | $-60.4K | $-15.2M | ||
| Q4 23 | — | $-14.0M | ||
| Q3 23 | — | $-17.7M |
| Q3 25 | 41.7% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 22.2% | — | ||
| Q3 24 | 21.8% | -38.7% | ||
| Q2 24 | 26.3% | -70.2% | ||
| Q1 24 | 26.3% | -72.7% | ||
| Q4 23 | — | -53.5% | ||
| Q3 23 | — | -124.9% |
| Q3 25 | -605.9% | — | ||
| Q2 25 | -460.5% | — | ||
| Q1 25 | -383.3% | — | ||
| Q3 24 | -433.4% | -1162.4% | ||
| Q2 24 | -364.0% | -1397.8% | ||
| Q1 24 | -362.8% | -1389.7% | ||
| Q4 23 | — | -1561.7% | ||
| Q3 23 | — | -1963.1% |
| Q3 25 | -508.9% | — | ||
| Q2 25 | -460.2% | — | ||
| Q1 25 | -1496.5% | — | ||
| Q3 24 | -28.1% | 6465.8% | ||
| Q2 24 | -11.0% | -1105.9% | ||
| Q1 24 | -6.6% | -1506.1% | ||
| Q4 23 | — | -1338.0% | ||
| Q3 23 | — | -2234.0% |
| Q3 25 | $0.12 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-0.06 | $1.44 | ||
| Q2 24 | $-0.02 | $-1.19 | ||
| Q1 24 | $-0.01 | $-2.62 | ||
| Q4 23 | — | $-1.90 | ||
| Q3 23 | — | $-2.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.2M | $765.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $134.2M | $-4.9M |
| Total Assets | $177.3M | $30.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $2.2M | — | ||
| Q2 25 | $1.6M | — | ||
| Q1 25 | $1.6M | — | ||
| Q3 24 | $12.2K | $765.0K | ||
| Q2 24 | $119.1K | $25.5M | ||
| Q1 24 | $3.6K | $25.5M | ||
| Q4 23 | — | $19.6M | ||
| Q3 23 | — | $26.4M |
| Q3 25 | $134.2M | — | ||
| Q2 25 | $139.2M | — | ||
| Q1 25 | $132.3M | — | ||
| Q3 24 | $-5.8M | $-4.9M | ||
| Q2 24 | $-4.9M | $-73.9M | ||
| Q1 24 | $-4.3M | $-68.8M | ||
| Q4 23 | — | $-53.8M | ||
| Q3 23 | — | $-43.3M |
| Q3 25 | $177.3M | — | ||
| Q2 25 | $185.4M | — | ||
| Q1 25 | $174.6M | — | ||
| Q3 24 | $20.9M | $30.6M | ||
| Q2 24 | $20.6M | $39.4M | ||
| Q1 24 | $37.3M | $37.3M | ||
| Q4 23 | — | $33.1M | ||
| Q3 23 | — | $42.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | $-8.9M |
| Free Cash FlowOCF − Capex | — | $-8.9M |
| FCF MarginFCF / Revenue | — | -892.5% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | -0.14× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-45.8M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $-482.6K | — | ||
| Q1 25 | $-64.1K | — | ||
| Q3 24 | $-686.5K | $-8.9M | ||
| Q2 24 | $-483.2K | $-11.7M | ||
| Q1 24 | $-498.8K | $-13.1M | ||
| Q4 23 | — | $-11.9M | ||
| Q3 23 | — | $-11.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-8.9M | ||
| Q2 24 | — | $-11.7M | ||
| Q1 24 | — | $-13.2M | ||
| Q4 23 | — | $-12.1M | ||
| Q3 23 | — | $-11.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -892.5% | ||
| Q2 24 | — | -1190.9% | ||
| Q1 24 | — | -1302.1% | ||
| Q4 23 | — | -1149.4% | ||
| Q3 23 | — | -1404.2% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 4.2% | ||
| Q4 23 | — | 17.4% | ||
| Q3 23 | — | 2.3% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -0.14× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
